Tablets under 20,000 for school children offer a practical balance of performance, portability, and affordability. They ...

Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep ...

In a classroom turned shelter for displaced families, teenager Ahmad Melhem follows a recorded lesson on a tablet as the war ...

A new study from NYU Langone Health partially attributed close to 2 million preterm births in 2018 — about 8% of the world’s ...

Allschwil, Switzerland – March 30, 2026 Idorsia Ltd (SIX: IDIA) announces positive top-line results from its Phase 2 ...

After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq (daridorexant) is one step closer to potentially becoming a first-in-class treatment for children. | After notching a phase 2 trial ...

Recently, Derek Robinette, Senior Pastor of Crestwood United Methodist Church, voiced his opposition to HB 829, which would ...

Mavacamten, the first-in-class cardiac myosin inhibitor approved for treatment of symptomatic adults with obstructive hypertrophic cardiomyopathy (HCM), is efficacious for adolescents with obstructive ...

Here is church information for March 28.

Screen time has long been a concern for parents, child safety advocates and others, particularly in the early years when a ...

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises ...

"This is a dangerous class of chemicals." New study links millions of preterm births and thousands of infant deaths to ...